Volume 10, Number 7—July 2004
Multiple rpoB Mutants of Mycobacterium tuberculosis and Second-order Selection
To the Editor: Rad and colleagues recently described variation in some genes involved in DNA repair (mutT2, mutT4, ogt) in Mycobacterium tuberculosis strains of different genotypes (1). This approach can also be used to investigate developing rifampin resistance in the context of emerging mutator alleles. Resistance to rifampin in M. tuberculosis strains is usually caused by the point mutations in the rpoB gene encoding the β-subunit of the DNA-dependent RNA polymerase, which is a target of the drug. Although a single point mutation is sufficient for developing rifampin resistance, a number of articles (2,3) describe multiple rpoB mutants for M. tuberculosis, i.e., rifampin-resistant strains harboring mutations in different codons of rpoB. Double, triple, and quadruple mutations in M. tuberculosis clinical isolates were reported in studies conducted throughout the world (2,3). Such emergence, albeit infrequent, of M. tuberculosis rpoB multiple mutants raises questions about their biologic importance and underlying mechanisms; answers to both remain elusive.
I propose an explanation of these observations in terms of second-order selection of hypermutable (mutator) alleles based on alterations in DNA repair genes. Unlike that of other antituberculosis drugs, resistance to rifampin is acquired in most M. tuberculosis isolates by altering a single target molecule and offers the most appropriate and straightforward model to demonstrate possible hypermutability in this species. In mycobacteria, hypermutability was demonstrated in vitro for M. smegmatis, a surrogate model for M. tuberculosis, as an increase in reversion (mutant to wild type) rate in rpoB526 or rpsL43 under counterselection by streptomycin or rifampin, respectively (4). A correlation between high mutation rate and antimicrobial resistance was reported for Pseudomonas aeruginosa isolates from lungs of cystic fibrosis patients (5). The mutator P. aeruginosa strains resulted from a defective mismatch-repair system (5). In M. tuberculosis, mismatch-repair genes (mutH, mutL, mutS, and recJ) were not found in its genome (6). However, the nucleotide pool in this species is exceptionally clean because of the presence of several copies of the mutT gene (1,6); the MutT protein removes oxidized guanines (8-Oxo-dGTP), thus counteracting replication or transcription errors. Consequently, the MutHLS mismatch-repair system simply may be not required in M. tuberculosis (6). Therefore, hypermutability in some strains of this species resulting in multiple rpoB mutants might develop under certain special (in vivo) circumstances through inactivation or down-regulation of some mutT genes. Further, the two most frequently described rpoB mutations are 531TCG→TTG and 526CAC→TAC. Both are cytosine-to-tymine transitions, which easily occur by spontaneous cytosine deamination to uracil. Indeed, M. tuberculosis is a G+C rich organism, therefore, it is naturally at high risk for cytosine deamination. Furthermore, pathogenic mycobacteria are at increased risk for deamination because of the production of reactive oxygen and nitrogen intermediates inside host macrophages. This deamination process is normally counteracted by uracil-N-glycosylase, the product of the ung gene, and organisms defective in the removal of uracil from DNA have an increased spontaneous mutation rate and more G:C→A:T base-pair transitions (7). Merchant et al., by using ung+ and ung-Escherichia coli strains, demonstrated that total nitric oxide exposures in the μmol/L range can lead to C→T mutations by a mechanism probably involving cytosine deamination (8). On the other hand, in M. smegmatis, the abrogation of the Ung activity leads not only to increased mutator phenotype but also to growth inhibition by reactive nitrogen intermediates (7). In summary, I speculate that mutations in ung that do not completely impair function, but do decrease synthesis of its product, might tolerably increase the spontaneous C→T mutations, including those in the respective positions in the rpoB codons 531 and 526. This assumption seems likely because both of the aforementioned particular mutations were described in in vitro–obtained spontaneous mutants of H37Rv and had a Darwinian fitness slightly less than and equal to that of the rpoB wild-type-susceptible parental strain (9). In contrast, the translesion synthesis-based pathways appear less likely to contribute to emergence of such mutants, although at least one of the translesion synthesis genes (dinP) is present in the genome of M. tuberculosis. In the E. coli in vitro model, a translesion synthesis enzyme (dinB encoded DNA polymerase IV) activity clearly promoted more important frameshift mutations (single-base deletions) in two thirds of the spontaneous mutants (10).
From an evolutionary point of view, the multiple rpoB mutations in M. tuberculosis have been hypothesized to arise as a compensatory mechanism to ameliorate the fitness costs of the original resistance mutation by a secondary mutation (11). The process of adaptation to the fitness costs of chromosomally encoded resistance has been studied in E. coli and Salmonella enterica serovar Typhi for mutations that affect translation in the rpsL and fusR genes (11) and for rpoB mutations in E. coli K12 strain (11). In the last instance, the rpoB multiple mutants were selected in vitro in a stepwise fashion, and one double mutant, L511Q+D516G (also described in M. tuberculosis strain ), exhibited a relative fitness either greater than or equal to either single mutant or the wild type. Reynolds (11) suggested that this allele is favored not merely as a combination of two low-level resistance mutations but also because these mutations together boost resistance and preserve fitness. Whether the same is true for other multiple mutant alleles in M. tuberculosis rpoB remains to be seen. Studying the costs of resistance of multiple rpoB mutations in a more realistic environment of animal models of TB infection seems promising.
- Rad ME, Bifani P, Martin C, Kremer K, Samper S, Rauzier J, Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis. 2003;9:838–45.
- Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol. 2001;39:2987–90.
- Pozzi G, Meloni M, Iona E, Orru G, Thoresen OF, Ricci ML, rpoB mutations in multi-drug resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol. 1999;37:1197–9.
- Karunkaran P, Davies J. Genetic antagonism and hypermutability in Mycobacterium smegmatis. J Bacteriol. 2000;182:3331–5.
- Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288:1251–3.
- Cole ST. Comparative mycobacterial genomics. Curr Opin Microbiol. 1998;1:567–71.
- Venkatesh J, Kumar P, Krishna PSM, Manjunath R, Varshnay U. Importance of uracil DNA glycosylase in Pseudomonas aeruginosa and Mycobacterium smegmatis, G+C rich bacteria, in mutation prevention, tolerance to acidified nitrite, and endurance in mouse macrophages. J Biol Chem. 2003;278:24350–8.
- Merchant K, Chen H, Gonzalez TC, Keefer LK, Shaw BR. Deamination of single-stranded DNA cytosine residues in aerobic nitric oxide solution at micromolar total NO exposures. Chem Res Toxicol. 1996;9:891–6.
- Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999;43:1866–9.
- Wagner J, Nohmi T. Escherichia coli DNA Polymerase IV mutator activity: genetic requirements and mutational specificity. J Bacteriol. 2000;182:4587–95.
- Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics. 2000;156:1471–81.
Suggested citation for this article: Mokrousov I. Multiple rpoB mutants of Mycobacterium tuberculosis and second-order selection. [letter]. Emerg Infect Dis [serial on the Internet]. 2004 Jul [date cited]. Available from: http://wwwnc.cdc.gov/eid/article/10/7/03-0598.htm